|
Jeffrey Cranmer
@
jeff_cranmer
Redwood City, CA
|
|
Executive Editor, @BioCentury. All opinions expressed are my own.
|
|
|
1.253
Tweetovi
|
367
Pratim
|
713
Osobe koje vas prate
|
| Tweetovi |
| Jeffrey Cranmer proslijedio/la je tweet | ||
|
Scott Gottlieb, MD
@ScottGottliebMD
|
10 h |
|
The speed by which @CDCgov made a substantial number of tests kits available to U.S. public health labs in rapid fashion (each of the 200 kits can test 700-800 specimens) shouldn’t be understated. This was an important and impressive achievement by our federal health officials. twitter.com/drnancym_cdc/s…
|
||
|
|
||
| Jeffrey Cranmer proslijedio/la je tweet | ||
|
steve usdin
@steveusdin1
|
10 h |
|
Gilead CEO says remdesivir patent dispute won’t affect access to the drug to treat #2019-nCoV outbreak.
biocentury.com/article/304390
WHO says remdesivir most promising treatment. biocentury.com/article/304374 pic.twitter.com/JKMxLPkZcN
|
||
|
|
||
| Jeffrey Cranmer proslijedio/la je tweet | ||
|
steve usdin
@steveusdin1
|
10 h |
|
FDA Oncology Center of Excellence Dir. Richard Pazdur supports expanded access for unapproved uses of approved drugs. This helps patients get access -- if insurers won't pay for an off-label use, a drug co can give it free under EA. biocentury.com/article/304382 pic.twitter.com/zczbFhyPGs
|
||
|
|
||
| Jeffrey Cranmer proslijedio/la je tweet | ||
|
Elizabeth S. Eaton
@LaboratoryLiz
|
11 h |
|
.@GileadSciences CEO O’Day says patients will be focus of its #2019nCoV response, not patents twitter.com/jeff_cranmer/s…
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
11 h |
|
$GILD O'Day reacts to Chinese institutes seeking to patent remdesivir for #2019nCov: 'We will not get in a patent dispute.' via @LaboratoryLiz @li_hongjiang in @BioCentury biocentury.com/article/304390
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
14 h |
|
My girl scout is very happy to exploit your weakness for thin mints.
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
15 h |
|
PTAB removes major overhang on $BIIB by upholding validity of patent for $4B #MultipleSclerosis therapy Tecfidera; it's all about aducanumab for #Alzheimers now.
@BioCentury's @StephenPHansen
reports: biocentury.com/article/304383
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
15 h |
|
2/2 “The whole point of expanded access is to provide therapies to patients,” says Pazdur.
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
15 h |
|
.@US_FDA's @realrickpazdur says he supports authorizing #ExpandedAccess requests for unapproved uses of approved medicines. @BioCentury's @steveusdin1 reports: biocentury.com/article/304382
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
18 h |
|
|
||
| Jeffrey Cranmer proslijedio/la je tweet | ||
|
Scott Gottlieb, MD
@ScottGottliebMD
|
5. velj |
|
Thailand has 25 confirmed cases, Japan 24, Singapore 24. The #coronavirus has continued to spread with Singapore, Malaysia, and Thailand reporting new infections that weren’t imported from China. They now seem to be suffering sustained local transmission. ibtimes.com/china-virus-de…
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
GWAR!
|
||
|
|
||
| Jeffrey Cranmer proslijedio/la je tweet | ||
|
steve usdin
@steveusdin1
|
5. velj |
|
Today: WHO says Gilead’s remdesivir most promising drug for #2019-nCoV. WHO plans master protocol to test multiple therapies. FDA authorizes emergency use Dx. HHS funds Regeneron coronavirus antibody. And more at biocentury.com/coronavirus. No paywall.
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
.@a16z's Vijay Pande tells @BioCentury's @_Ktktktktk the firm is investing new $750M fund in “weak AI” -- speeding and scaling up tasks humans can do -- while tech that could enable “strong AI,” which does things humans can’t do, matures. biocentury.com/article/304379
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
At least 22 MNCs are sponsoring interventional trials in China, 18 have trial sites in Wuhan, the epicenter of the #2019nCoV outbreak. An analysis of cos most active in the region finds Roche could be most affected. via @BioCentury biocentury.com/article/304378 pic.twitter.com/UhUM5dh5VE
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
CEO O'Day: $GILD has sense of "urgency" for M&A, seeking “transformative" deals a la $GLPG, as well as small- to medium-sized bolt-on takeouts. Co also working “night and day” to ramp up manufacturing for #2019nCoV therapy via @BioCentury's @LaboratoryLiz biocentury.com/article/304375
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
.@WHO draft report: $GILD's remdesivir most "promising" candidate to treat #2019nCoV, planning for trial under way. $GILD says its “investing pretty heavily” in manufacturing of the therapy “to make sure we’re prepared as best as we can” via @BioCentury biocentury.com/article/304374
|
||
|
|
||
| Jeffrey Cranmer proslijedio/la je tweet | ||
|
Scott Gottlieb, MD
@ScottGottliebMD
|
4. velj |
|
Thread: There are now 2 deaths in 146 patients diagnosed with #coronavirus outside China. It’s a case fatality rate of 1.37%. This may be our best estimate to date. The patients include mild disease as well those presenting with pneumonia. It tracks with 2% CFR reported in China.
|
||
|
|
||
| Jeffrey Cranmer proslijedio/la je tweet | ||
|
Scott Gottlieb, MD
@ScottGottliebMD
|
4. velj |
|
Great work by #FDA to take a key step toward being able to expand testing for #coronavirus to state and local public health labs. fda.gov/news-events/pr…
|
||
|
|
||
|
Jeffrey Cranmer
@jeff_cranmer
|
4. velj |
|
$CTLT raises $500M in part to pay for takeout of @MaSTherCell. Price is nearly 16x the cell/gene therapy CDMO's '18 rev of €17.4M - Catalent paid 6x for Paragon last year. Sign of increasing competition for manufacturing capacity in new modalities? biocentury.com/article/304361
|
||
|
|
||